Ascendis Pharma (NASDAQ: ASND) reported Q3 EPS of (EUR1.72), EUR0.18 worse than the analyst estimate of (EUR1.54). Revenue for the quarter came in at EUR57.83 million versus the consensus estimate of EUR68.42 million.

Financial Update and Outlook Based on Current Plans

As of September 30, 2024, Ascendis Pharma had cash, cash equivalents, and marketable securities, totaling €626 million, compared to €399 million as of December 31, 2023.
Full year 2024 SKYTROFA revenue excluding sales deductions related to prior years expected to be €200 - €220 million.
Expect total operating expenses (SG&A and R&D) to be approximately €600 million for 2024.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.